Co-Diagnostics, Inc. (CODX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1897632048
Co-Diagnostics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 622,489.00 USD |
| Gross profit | 400,112.00 USD |
| Operating income | -50.17 m USD |
| EBIT | -48.51 m USD |
| Net income | -46.90 m USD |
| Diluted EPS – continuing operations | -35.25 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
More stocks
- CV Sciences, Inc. (CVSI)
- PSQ Holdings, Inc. (PSQH)
- BioNexus Gene Lab Corp (BGLC)
- Iveda Solutions, Inc. (IVDA)
- ADAMANT DRI PROCESSING & MINERALS GROUP (ADMG)
- RELIABILITY INC (RLBY)
- 20/20 Biolabs, Inc. (AIDX)
- BioAtla, Inc. (BCAB)
- Cannabis Bioscience International Holdings, Inc. (CBIH)
- LQR House Inc. (YHC)
- TurnOnGreen, Inc. (TOGI)
- BioXcel Therapeutics, Inc. (BTAI)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.